Daiichi Sankyo Europe: New secondary analysis of CLEAR Outcomes data for bempedoic acid show significant risk reduction of total cardiovascular events and no increase of new-onset diabetes in patients at high-risk of cardiovascular disease finanznachrichten.de - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from finanznachrichten.de Daily Mail and Mail on Sunday newspapers.
Daiichi Sankyo Europe GmbH: Four-year follow-up data reinforces the consistent effectiveness and safety of treatment with edoxaban in patients with atrial fibrillation (AF) finanznachrichten.de - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from finanznachrichten.de Daily Mail and Mail on Sunday newspapers.
Four-year follow-up data reinforces the consistent effectiveness and safety of treatment with edoxaban in patients with atrial fibrillation (AF) streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.
Successful topline results from the CLEAR Outcomes Trial demonstrate that bempedoic acid, marketed as NILEMDO? in Europe, reduces the risk of serious cardiovascular (CV) events in patients with